Latest on ultra-rare disease approval; Positive, if mixed, signs for Biogen's ALS drug; Clay Siegall finds a new job; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
Over the last four years, we’ve honored 80 women whose extraordinary accomplishments have changed the game in biopharma R&D. You can now nominate someone to be highlighted in this year’s special report. Details are here.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.